Additional file 1 of Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

Additional file 1. Table S1. The primary efficacy outcomes from the “Children of 1997” birth cohort. Table S2. The safety outcomes from the “Children of 1997” birth cohort. Table S3. The genetic variants selected for the HMGCR score and PCSK9 score and their association in the Global Lipids Genetics Consortium and the “Children of 1997” birth cohort. Table S4. The effect of genetic inhibition of HMGCR and PCSK9 on coronary artery disease in East Asian. Table S5. The effect of genetic inhibition of HMGCR and PCSK9 on efficacy outcomes in the “Children of 1997” birth cohort. Table S6. The effect of genetic inhibition of HMGCR and PCSK9 on efficacy outcomes using complete case analysis in the “Children of 1997” birth cohort. Table S7. The effect of genetic inhibition of HMGCR and PCSK9 (using index variant) on efficacy outcomes in the “Children of 1997” birth cohort. Table S8. The effect of genetic inhibition of HMGCR and PCSK9 on safety outcomes in the “Children of 1997” birth cohort. Table S9. The effect of genetic inhibition of HMGCR and PCSK9 on safety outcomes using complete case analysis in the “Children of 1997” birth cohort. Table S10. The effect of genetic inhibition of HMGCR and PCSK9 (using index variant) on safety outcomes in the “Children of 1997” birth cohort. Supplementary Note. R code for Mendelian randomization analysis, principal component analysis, and visualization.

补充材料1。
附表S1：1997年出生队列（Children of 1997 birth cohort）的主要疗效结局。
附表S2：1997年出生队列的安全性结局。
附表S3：为构建HMGCR评分与PCSK9评分所筛选的遗传变异，及其在全球脂质遗传学联盟（Global Lipids Genetics Consortium）与1997年出生队列中的关联特征。
附表S4：东亚人群中HMGCR与PCSK9的遗传抑制作用对冠状动脉疾病的影响。
附表S5：1997年出生队列中HMGCR与PCSK9的遗传抑制作用对疗效结局的影响。
附表S6：采用完整病例分析的1997年出生队列中HMGCR与PCSK9的遗传抑制作用对疗效结局的影响。
附表S7：采用索引变异的1997年出生队列中HMGCR与PCSK9的遗传抑制作用对疗效结局的影响。
附表S8：1997年出生队列中HMGCR与PCSK9的遗传抑制作用对安全性结局的影响。
附表S9：采用完整病例分析的1997年出生队列中HMGCR与PCSK9的遗传抑制作用对安全性结局的影响。
附表S10：采用索引变异的1997年出生队列中HMGCR与PCSK9的遗传抑制作用对安全性结局的影响。
补充说明：孟德尔随机化分析（Mendelian randomization analysis）、主成分分析（principal component analysis）及可视化的R代码。